73 results
8-K
EX-99.1
TEVA
Teva- Pharmaceutical Industries Ltd.
8 May 24
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
7:01am
consisted of $64 million attributable to an update to the estimated settlement provision for the Company’s opioid litigation (mainly the effect … and regulatory action in connection with public concern over the abuse of opioid medications; our ability to timely make
Page 13 of 14
payments
8-K
EX-99.1
TEVA
Teva- Pharmaceutical Industries Ltd.
31 Jan 24
Results of Operations and Financial Condition
7:00am
in connection with public concern over the abuse of opioid medications; our ability to timely make payments required under our nationwide opioids
8-K
EX-99.1
fzrre 3h4trggm5
8 Nov 23
2023 revenues outlook revised to $15.1 - $15.5 billion from $15.0 - $15.4 billion
7:01am
8-K
EX-99.1
i5yxsj tl
2 Aug 23
Results of Operations and Financial Condition
7:00am
8-K
EX-99.1
ualmp8fpw
8 Jun 23
Teva Concludes Nationwide Opioids Settlement Agreement
8:30am
8-K
qdt n976vc
8 Jun 23
Teva Concludes Nationwide Opioids Settlement Agreement
8:30am
8-K
EX-99.1
tg4b4ib0 1h8tm
10 May 23
Results of Operations and Financial Condition
7:01am
8-K
EX-99.1
rsn7w5yw5p
3 Nov 22
Key financial highlights and outlook
7:00am
8-K
EX-99.1
47qg6u72kp4
26 Jul 22
Key financial highlights and outlook
4:56pm